Daniel Morgensztern, M.D.
Washington University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Morgensztern, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:39 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05049863 · Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)Washington University School of Medicine · terminated · Small-cell Lung Cancer, Small Cell Lung Carcinoma · principal investigator
- Ph2NCT05007769 · Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCWashington University School of Medicine · withdrawn · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC · principal investigator
- Ph2NCT04791839 · Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerWashington University School of Medicine · active not recruiting · Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03689855 · Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLCWashington University School of Medicine · completed · Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC · principal investigator
- N/ANCT02431169 · Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease ProgressionWashington University School of Medicine · terminated · Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer · principal investigator
- Ph1NCT02342353 · Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)Washington University School of Medicine · terminated · Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph2NCT02193152 · Pazopanib in Molecularly Selected Patients With Advanced NSCLCWashington University School of Medicine · terminated · Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer · principal investigator
- Ph2NCT00442507 · Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal JunctionWashington University School of Medicine · terminated · Esophageal Neoplasms, Esophageal Diseases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.